Business

Chinese Biopharmaceutical Contract Manufacturing Market 2021

Written by Stella01wilson

Roots Analysis is pleased to announce the publication of its recent study, titled, “China Biopharmaceutical Contract Manufacturing Market, 2021-2030.”

Owing to benefits, such as reduced manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, biopharmaceutical developers from across the globe, are increasingly outsourcing their manufacturing operations to China based CMOs. Further, in order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives.

Read More: https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of biopharmaceuticals in China. The study also features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of companies offering contract manufacturing services for biopharmaceuticals in China.
  • An analysis of the partnerships that have been established in this domain, in the recent past.
  • An analysis of the expansion initiatives undertaken by contract manufacturers in China, in order to augment their capabilities, in the recent past.
  • A detailed analysis of more than 1500 clinical trials related to biopharmaceuticals that have been / are being / are likely to be conducted in China.
  • An estimate of the overall, installed capacity for manufacturing biopharmaceuticals, based on data reported by industry stakeholders in the public domain.
  • An analysis of the initiatives of big biopharma players engaged in this domain.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by drug / therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • Detailed profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biopharmaceutical products.
  • A case study comparing the key characteristics of large molecule and small molecule drugs.
  • A discussion on industry affiliated trends, key drivers, and challenges, under a SWOT framework, which are likely to impact the evolution of this field.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Ask for PDF Sample @ https://www.rootsanalysis.com/reports/313/request-sample.html

Type of Product

  • API
  • FDF

Type of Expression System Used

  • Mammalian
  • Microbial
  • Others

Scale of Operation

  • Preclinical / Clinical
  • Commercial

Size of Manufacturer

  • Small
  • Mid-sized
  • Large / Very Large

Type of Biologic

  • Antibody
  • Vaccine
  • Others

Key companies covered in the report

  • ChemPartner Biologics
  • JHL Biotech
  • JOINN Biologics
  • MabPlex
  • Mycenax Biotech
  • WuXi AppTec

Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Case Study: Comparison of Small Molecules and Large Molecules
  5. Competitive Landscape
  6. Company Profiles
  7. Partnerships
  8. Recent Expansions
  9. Clinical Trial Analysis
  10. Regional Capability Analysis
  11. Capacity Analysis
  12. Big Pharma Biopharmaceutical Manufacturing Initiatives in China
  13. Make Versus Buy Decision Making Framework
  14. Market Sizing and Opportunity Analysis
  15. COVID-19 Impact on China Biopharmaceutical CMO Market
  16. SWOT Analysis
  17. Future of the China Biopharmaceutical CMO Market
  18. Interview Transcripts
  19. APPENDIX 1: TABULATED DATA
  20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Get Customize Report @ https://www.rootsanalysis.com/reports/313/request-customization.html

Also Visit Our Latest Publication

https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html

https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html

https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html

https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html

 

About the author

Stella01wilson

Leave a Comment